Please login to the form below

Not currently logged in
Email:
Password:

ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director

Thomas ClayBelgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires.

Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his father, Landon Clay.

He said: “I Am very honoured to be appointed as chairman of the board of ThromboGenics at a time when the company is starting to make excellent progress with its exciting pipeline of four novel therapies for treating diabetic eye disease.”

Clay is also vice-president of East Hill Management, a US-based investment company and serves as chairman and CEO of Golden Queen Mining and as a director of the Clay Mathematics Institute.

Patrik De Haes, chief executive officer of ThromboGenics, said: “I am delighted that Thomas has agreed to take on the role of chairman, his rich experience and deep understanding of ThromboGenics and life sciences in general will be invaluable for the company in achieving its objectives going forward.”

27th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics